Analysis: Jubilant Pharmova Limited

NSE:JUBLPHARMA Pharma - API & CRAMS Market cap: ₹14.4K cr

Growth thesis

Jubilant Pharmova is a diversified specialty pharma company with Radiopharma, CDMO Sterile Injectables, Allergy Immunotherapy, and CRDMO segments. Key growth drivers include Line 3 at Spokane (peak $80-90M revenue in 1.5-2 years), MIBG orphan drug approval (H2 FY2027), and Ruby-Fill® expansion (30%+ YoY growth). Management has repeatedly delayed targets: Radiopharma breakeven shifted from Q4 FY24 to FY25, Montreal losses persist into FY2028, and API growth remains flat. While FY2027 guidance shows low double-digit revenue growth and margin improvement to 17-18%, execution risks loom over $200M Spokane Line 4 capex, EU choline chloride market entry, and resolving Montreal’s $87M pending capex. The business could scale to Rs 13,500 crore revenue by FY30 if CAPEX timelines hold, but margin upgrades depend on resolving operational delays.

Why is Jubilant Pharmova Limited stock rising?

Line 3 at Spokane to commence commercial production in late FY2027 with 10+ products including a top oncology product, expecting peak revenue of $80-90 million 1.5-2 years earlier than projected.
Line 3 tech transfer revenues of $60-80 million expected in FY2027.
Line 4 at Spokane and Line 5 at Montreal capex ongoing; remaining spend $34 million and $87 million respectively.
PET pharmacy network: first three sites to be commercialized in FY2028; peak ramp expected in 3-4 years.
MIBG NDA filing targeted for H2 FY2027 with accelerated FDA review due to orphan drug designation; self-commercialization planned.

Research report

companyname: Jubilant Pharmova Limited ticker: JUBLPHARMA sector: Specialty Pharmaceuticals Jubilant Pharmova Limited is a global integrated pharmaceutical company that operates six distinct businesses under one roof. It is part of the Jubilant Bhartia Group, founded in 1978, and employs over 5,500 people worldwide. The company makes and sells radiopharmaceuticals, allergy immunotherapy extracts, sterile injectables for contract customers, drug discovery and API manufacturing services, generic ...

Read the full report →

Catalysts

capex, margin expansion, regulatory approval, geographic expansion

Growth guidance

FY2027 consolidated revenue growth guided at low double digits with EBITDA margin expected to remain in 38-40% range

Guidance no_data

Management consistency

mixed

RS rating: 55 Stage: Stage 1

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Jubilant Pharmova Limited and 4,900+ companies.

5-day free pass. No card required.